Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
Globe Newswire•05/08/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.